Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued Monday for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea and vomiting.

Acacia, which lost €0.91 (23%) to €3.04 on Monday, said it still anticipates a 1H19 launch of the product...